1st Quarter - Report

NOVO NORDISK INC. for NOVO NORDISK INC.

Firm
Client
Income
—
Expenses
$600,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

HR 8 American Taxpayer Relief Act (R&D tax credit) of 2012 (R&D credit)

Contacted: Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 8 (113th)

Trade (domestic/foreign) TRD

EU/US Transatlantic Trade and Investment Partnership (TTIP) (intellectual property); Trans-Pacific Partnership (TPP); intellectual property

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH)

Health Issues HCR

National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), Prevention and Public Health Fund, AHRQ and USPSTF diabetes screening standards;diabetes issues in Healthy People 2020 and the Office of Disease Prevention and Health Promotion (ODPHP); H.R. 1074 and S 539 National Diabetes Clinical Care Commission Act of 2013; human growth / rare disorders awareness; H.R. 8 American Taxpayer Relief Act (Special Diabetes Program reauthorization); gestational diabetes; diabetes disparities; H.R. 351 and S. 351 Protecting Seniors' Access to Medicare Act of 2013 (IPAB repeal)

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Executive Office of the President (EOP); Natl Institutes of Health (NIH); SENATE

Bills named: S. 351 (113th), H.R. 8 (113th), H.R. 1074 (113th), H.R. 351 (113th)

Medicare/Medicaid MMM

Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 and H.R. 8 American Taxpayer Relief Actof 2012; H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally

Contacted: SENATE; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Executive Office of the President (EOP)

Bills named: S. 452 (113th), H.R. 8 (113th), H.R. 1257 (113th), H.R. 1274 (113th), H.R. 962 (113th)

Budget/Appropriations BUD

Issues related to Medicare Part D, FDA and patents in S. Con. Res. 8 FY14 Senate Budget Resolution; H Con Res. 25 House Budget Resolution; Modernizing cost estimates with respect to preventive health legislation (CBO scoring); National Diabetes Prevention Program; HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013

Contacted: Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS)

Bills named: H.Con.Res. 25 (113th), H.R. 933 (113th), S.Con.Res. 8 (113th)

Pharmacy PHA

Issues regarding Pharmaceutical Traceability Enhancement Code (Rx TEC) Act and discussion draft on serialization (track and trace); S.622 -- Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013 for amendments that would impact human drug user fees; issues regarding biosimilars; 340B

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; SENATE; Executive Office of the President (EOP); Centers For Disease Control & Prevention (CDC)

Bills named: S. 622 (113th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
NOVO A/S Denmark Denmark 25.5% —
NOVO NORDISK FONDEN (FOUNDATION) Denmark Denmark 25.5% —
NOVO NORDISK A/S Denmark Denmark 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.